Download PDF
Semin Liver Dis 2014; 34(02): 115-122
DOI: 10.1055/s-0034-1375953
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Epidemiology and Risk Factors for Idiosyncratic Drug-Induced Liver Injury

Einar S. Björnsson
1   Department of Internal Medicine, The Division of Gastroenterology and Hepatology, The National University Hospital of Iceland, Reykjavik, Iceland
› Author Affiliations
Further Information

Publication History

Publication Date:
31 May 2014 (online)

    Permissions and Reprints

Abstract

Idiosyncratic drug-induced liver injury (DILI) is, like other adverse effects of drugs, underreported and underestimated in most epidemiological studies based on registries of DILI cases and reporting systems (e.g., Medwatch). The same is probably true for prospective population-based studies, although they are much more likely to mirror the true incidence of DILI. Despite these challenges, the epidemiology of DILI remains of utmost importance and is gradually coming into better focus. A recent population based study found a crude incidence of ∼19 cases per 100,000 per year. Certain agents are particularly noteworthy for their DILI risk. Amoxicillin-clavulanate continues to be the most commonly implicated agent occurring in ∼1 out of 2,300 users. Some others that standout with significantly higher risk include azathioprine and infliximab. Although statin-induced hepatotoxicity has been well documented, the risk is probably quite low. Overall, the majority of DILI in children and adults is associated with either antibiotics or anticonvulsants. Drug-induced liver injury associated with intravenously given drugs does not show any major differences from DILI due to orally administered agents. Unfortunately, our understanding of pretherapy risk assessment remains rudimentary for the most part.

Keywords

drug-induced liver injury - incidence - hepatotoxicity - epidemiology - risk factors
 

  • References

  • 1 Larrey D. Epidemiology and individual susceptibility to adverse drug reactions affecting the liver. Semin Liver Dis 2002; 22 (2) 145-155
    Article in Thieme ConnectPubMedGoogle Scholar
  • 2 Navarro VJ, Senior JR. Drug-related hepatotoxicity. N Engl J Med 2006; 354 (7) 731-739
    CrossrefPubMedGoogle Scholar
  • 3 Watkins PB, Seeff LB. Drug-induced liver injury: summary of a single topic clinical research conference. Hepatology 2006; 43 (3) 618-631
    CrossrefPubMedGoogle Scholar
  • 4 Bell LN, Chalasani N. Epidemiology of idiosyncratic drug-induced liver injury. Semin Liver Dis 2009; 29 (4) 337-347
    Article in Thieme ConnectPubMedGoogle Scholar
  • 5 Björnsson E. Review article: drug-induced liver injury in clinical practice. Aliment Pharmacol Ther 2010; 32 (1) 3-13
    PubMedGoogle Scholar
  • 6 Björnsson ES, Bergmann OM, Björnsson HK, Kvaran RB, Olafsson S. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology 2013; 144 (7) 1419-1425 , e1–e3, quiz e19–e20
    CrossrefPubMedGoogle Scholar
  • 7 Begaud B, Martin K, Haramburu F, Moore N. Rates of spontaneous reporting of adverse drug reactions in France. JAMA 2002; 288 (13) 1588
    CrossrefPubMedGoogle Scholar
  • 8 Sgro C, Clinard F, Ouazir K , et al. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology 2002; 36 (2) 451-455
    CrossrefPubMedGoogle Scholar
  • 9 Olsson R, Brunlöf G, Johansson ML, Persson M. Drug-induced hepatic injury in Sweden. Hepatology 2003; 38 (2) 531-532
    PubMedGoogle Scholar
  • 10 Lee WM, Senior JR. Recognizing drug-induced liver injury: current problems, possible solutions. Toxicol Pathol 2005; 33 (1) 155-164
    CrossrefPubMedGoogle Scholar
  • 11 de Abajo FJ, Montero D, Madurga M, García Rodríguez LA. Acute and clinically relevant drug-induced liver injury: a population based case-control study. Br J Clin Pharmacol 2004; 58 (1) 71-80
    CrossrefPubMedGoogle Scholar
  • 12 De Valle MB, Av Klinteberg V, Alem N, Olsson R, Björnsson E. Drug-induced liver injury in a Swedish University hospital out-patient hepatology clinic. Aliment Pharmacol Ther 2006; 24 (8) 1187-1195
    CrossrefPubMedGoogle Scholar
  • 13 Andrade RJ, Lucena MI, Fernández MC , et al; Spanish Group for the Study of Drug-Induced Liver Disease. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 2005; 129 (2) 512-521
    CrossrefPubMedGoogle Scholar
  • 14 Björnsson E, Olsson R. Outcome and prognostic markers in severe drug-induced liver disease. Hepatology 2005; 42 (2) 481-489
    CrossrefPubMedGoogle Scholar
  • 15 Chalasani N, Fontana RJ, Bonkovsky HL , et al; Drug Induced Liver Injury Network (DILIN). Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 2008; 135 (6) 1924-1934 , e1–e4
    CrossrefPubMedGoogle Scholar
  • 16 Navarro VJ, Barnhart HX, Bonkovsky HL , et al. The rising burden of herbal and dietary supplement induced hepatotoxicity in the USA. Hepatology 2013; 58: 264A
    PubMedGoogle Scholar
  • 17 Ibáñez L, Pérez E, Vidal X, Laporte JR ; Grup d'Estudi Multicènteric d'Hepatotoxicitat Aguda de Barcelona (GEMHAB). Prospective surveillance of acute serious liver disease unrelated to infectious, obstructive, or metabolic diseases: epidemiological and clinical features, and exposure to drugs. J Hepatol 2002; 37 (5) 592-600
    CrossrefPubMedGoogle Scholar
  • 18 Pérez Gutthann S, García Rodríguez LA. The increased risk of hospitalizations for acute liver injury in a population with exposure to multiple drugs. Epidemiology 1993; 4 (6) 496-501
    CrossrefPubMedGoogle Scholar
  • 19 García Rodríguez LA, Ruigómez A, Jick H. A review of epidemiologic research on drug-induced acute liver injury using the general practice research data base in the United Kingdom. Pharmacotherapy 1997; 17 (4) 721-728
    PubMedGoogle Scholar
  • 20 García Rodríguez LA, Stricker BH, Zimmerman HJ. Risk of acute liver injury associated with the combination of amoxicillin and clavulanic acid. Arch Intern Med 1996; 156 (12) 1327-1332
    CrossrefPubMedGoogle Scholar
  • 21 Jinjuvadia K, Kwan W, Fontana RJ. Searching for a needle in a haystack: use of ICD-9-CM codes in drug-induced liver injury. Am J Gastroenterol 2007; 102 (11) 2437-2443
    CrossrefPubMedGoogle Scholar
  • 22 Devarbhavi H, Dierkhising R, Kremers WK, Sandeep MS, Karanth D, Adarsh CK. Single-center experience with drug-induced liver injury from India: causes, outcome, prognosis, and predictors of mortality. Am J Gastroenterol 2010; 105 (11) 2396-2404
    CrossrefPubMedGoogle Scholar
  • 23 Idilman R, Bektas M, Cinar K , et al. The characteristics and clinical outcome of drug-induced liver injury: a single-center experience. J Clin Gastroenterol 2010; 44 (6) e128-e132
    CrossrefPubMedGoogle Scholar
  • 24 Russo MW, Scobey M, Bonkovsky HL. Drug-induced liver injury associated with statins. Semin Liver Dis 2009; 29 (4) 412-422
    Article in Thieme ConnectPubMedGoogle Scholar
  • 25 Björnsson E, Jacobsen EI, Kalaitzakis E. Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing. J Hepatol 2012; 56 (2) 374-380
    CrossrefPubMedGoogle Scholar
  • 26 Bergmann OM, Kristjansson G, Jonasson JG, Björnsson ES. Jaundice due to suspected statin hepatotoxicity: a case series. Dig Dis Sci 2012; 57 (7) 1959-1964
    CrossrefPubMedGoogle Scholar
  • 27 Bader T. The myth of statin-induced hepatotoxicity. Am J Gastroenterol 2010; 105 (5) 978-980
    CrossrefPubMedGoogle Scholar
  • 28 Charles EC, Olson KL, Sandhoff BG, McClure DL, Merenich JA. Evaluation of cases of severe statin-related transaminitis within a large health maintenance organization. Am J Med 2005; 118 (6) 618-624
    CrossrefPubMedGoogle Scholar
  • 29 Perger L, Kohler M, Fattinger K, Flury R, Meier PJ, Pauli-Magnus C. Fatal liver failure with atorvastatin. J Hepatol 2003; 39 (6) 1095-1097
    PubMedGoogle Scholar
  • 30 Duh MS, Walker AM, Kronlund Jr KH. Descriptive epidemiology of acute liver enzyme abnormalities in the general population of central Massachusetts. Pharmacoepidemiol Drug Saf 1999; 8 (4) 275-283
    CrossrefPubMedGoogle Scholar
  • 31 Meier Y, Cavallaro M, Roos M , et al. Incidence of drug-induced liver injury in medical inpatients. Eur J Clin Pharmacol 2005; 61 (2) 135-143
    CrossrefPubMedGoogle Scholar
  • 32 Malchow-Møller A, Matzen P, Bjerregaard B , et al. Causes and characteristics of 500 consecutive cases of jaundice. Scand J Gastroenterol 1981; 16 (1) 1-6
    PubMedGoogle Scholar
  • 33 Björnsson E, Ismael S, Nejdet S, Kilander A. Severe jaundice in Sweden in the new millennium: causes, investigations, treatment and prognosis. Scand J Gastroenterol 2003; 38 (1) 86-94
    CrossrefPubMedGoogle Scholar
  • 34 Vuppalanchi R, Liangpunsakul S, Chalasani N. Etiology of new-onset jaundice: how often is it caused by idiosyncratic drug-induced liver injury in the united states. Am J Gastroenterol 2007; 10 2 (3) 558-562 , quiz 693
    PubMedGoogle Scholar
  • 35 Ostapowicz G, Fontana RJ, Schiødt FV , et al; U.S. Acute Liver Failure Study Group. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 2002; 137 (12) 947-954
    CrossrefPubMedGoogle Scholar
  • 36 Russo MW, Galanko JA, Shrestha R, Fried MW, Watkins P. Liver transplantation for acute liver failure from drug induced liver injury in the United States. Liver Transpl 2004; 10 (8) 1018-1023
    CrossrefPubMedGoogle Scholar
  • 37 Ohmori S, Shiraki K, Inoue H , et al. Clinical characteristics and prognostic indicators of drug-induced fulminant hepatic failure. Hepatogastroenterology 2003; 50 (53) 1531-1534
    PubMedGoogle Scholar
  • 38 Wei G, Bergquist A, Broomé U , et al. Acute liver failure in Sweden: etiology and outcome. J Intern Med 2007; 262 (3) 393-401
    CrossrefPubMedGoogle Scholar
  • 39 Björnsson E, Jerlstad P, Bergqvist A, Olsson R. Fulminant drug-induced hepatic failure leading to death or liver transplantation in Sweden. Scand J Gastroenterol 2005; 40 (9) 1095-1101
    CrossrefPubMedGoogle Scholar
  • 40 Reuben A, Koch DG, Lee WM ; Acute Liver Failure Study Group. Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. Hepatology 2010; 52 (6) 2065-2076
    CrossrefPubMedGoogle Scholar
  • 41 Ghabril M, Fontana R, Rockey D, Jiezhun G, Chalasani N. Drug-induced liver injury caused by intravenously administered medications: the Drug-Induced Liver Injury Network experience. J Clin Gastroenterol 2013; 47 (6) 553-558
    CrossrefPubMedGoogle Scholar
  • 42 Squires Jr RH, Shneider BL, Bucuvalas J , et al. Acute liver failure in children: the first 348 patients in the pediatric acute liver failure study group. J Pediatr 2006; 148 (5) 652-658
    CrossrefPubMedGoogle Scholar
  • 43 Devarbhavi H, Karanth D, Prasanna KS, Adarsh CK, Patil M. Drug-Induced liver injury with hypersensitivity features has a better outcome: a single-center experience of 39 children and adolescents. Hepatology 2011; 54 (4) 1344-1350
    CrossrefPubMedGoogle Scholar
  • 44 Molleston JP, Fontana RJ, Lopez MJ, Kleiner DE, Gu J, Chalasani N ; Drug-Induced Liver Injury Network. Characteristics of idiosyncratic drug-induced liver injury in children: results from the DILIN prospective study. J Pediatr Gastroenterol Nutr 2011; 53 (2) 182-189
    CrossrefPubMedGoogle Scholar
  • 45 Björnsson E, Nordlinder H, Olsson R. Clinical characteristics and prognostic markers in disulfiram-induced liver injury. J Hepatol 2006; 44 (4) 791-797
    CrossrefPubMedGoogle Scholar
  • 46 Björnsson E, Kalaitzakis E, Olsson R. The impact of eosinophilia and hepatic necrosis on prognosis in patients with drug-induced liver injury. Aliment Pharmacol Ther 2007; 25 (12) 1411-1421
    CrossrefPubMedGoogle Scholar
  • 47 Kleiner DE, Chalasani NP, Lee WM , et al; Drug-Induced Liver Injury Network (DILIN). Hepatic histological findings in suspected drug-induced liver injury: Systematic evaluation and clinical associations. Hepatology 2014; 59 (2) 661-670
    CrossrefPubMedGoogle Scholar
  • 48 Daly AK, Donaldson PT, Bhatnagar P , et al; DILIGEN Study; International SAE Consortium. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet 2009; 41 (7) 816-819
    CrossrefPubMedGoogle Scholar
  • 49 Papay JI, Clines D, Rafi R , et al. Drug-induced liver injury following positive drug rechallenge. Regul Toxicol Pharmacol 2009; 54 (1) 84-90
    CrossrefPubMedGoogle Scholar
  • 50 Lucena MI, Andrade RJ, Fernández MC , et al; Spanish Group for the Study of Drug-Induced Liver Disease (Grupo de Estudio para las Hepatopatías Asociadas a Medicamentos (GEHAM)). Determinants of the clinical expression of amoxicillin-clavulanate hepatotoxicity: a prospective series from Spain. Hepatology 2006; 44 (4) 850-856
    CrossrefPubMedGoogle Scholar
  • 51 Stricker BH, Blok AP, Claas FH, Van Parys GE, Desmet VJ. Hepatic injury associated with the use of nitrofurans: a clinicopathological study of 52 reported cases. Hepatology 1988; 8 (3) 599-606
    CrossrefPubMedGoogle Scholar
  • 52 Olsson R, Wiholm BE, Sand C, Zettergren L, Hultcrantz R, Myrhed M. Liver damage from flucloxacillin, cloxacillin and dicloxacillin. J Hepatol 1992; 15 (1-2) 154-161
    CrossrefPubMedGoogle Scholar
  • 53 Fountain FF, Tolley E, Chrisman CR, Self TH. Isoniazid hepatotoxicity associated with treatment of latent tuberculosis infection: a 7-year evaluation from a public health tuberculosis clinic. Chest 2005; 128 (1) 116-123
    CrossrefPubMedGoogle Scholar
  • 54 Stock JG, Strunin L. Unexplained hepatitis following halothane. Anesthesiology 1985; 63 (4) 424-439
    CrossrefPubMedGoogle Scholar
  • 55 Lucena MI, Andrade RJ, Kaplowitz N , et al; Spanish Group for the Study of Drug-Induced Liver Disease. Phenotypic characterization of idiosyncratic drug-induced liver injury: the influence of age and sex. Hepatology 2009; 49 (6) 2001-2009
    CrossrefPubMedGoogle Scholar
  • 56 Petronijevic M, Ilic K, Suzuki A. Drug induced hepatotoxicity: data from the Serbian pharmacovigilance database. Pharmacoepidemiol Drug Saf 2011; 20 (4) 416-423
    CrossrefPubMedGoogle Scholar
  • 57 Zimmerman HJ. Hepatoxicity. The Adverse Effects of Drugs and Other Chemicals on the Liver. (2nd ed.). Philadelphia, PA: Lippincott Williams & Wilkins; 1999
    Google Scholar
  • 58 Björnsson E, Talwalkar J, Treeprasertsuk S , et al. Drug-induced autoimmune hepatitis: clinical characteristics and prognosis. Hepatology 2010; 51 (6) 2040-2048
    CrossrefPubMedGoogle Scholar
  • 59 Herrlinger C, Klotz U. Drug metabolism and drug interactions in the elderly. Best Pract Res Clin Gastroenterol 2001; 15 (6) 897-918
    CrossrefPubMedGoogle Scholar
  • 60 Steele MA, Burk RF, DesPrez RM. Toxic hepatitis with isoniazid and rifampin. A meta-analysis. Chest 1991; 99 (2) 465-471
    CrossrefPubMedGoogle Scholar
  • 61 Gopaul S, Farrell K, Abbott F. Effects of age and polytherapy, risk factors of valproic acid (VPA) hepatotoxicity, on the excretion of thiol conjugates of (E)-2,4-diene VPA in people with epilepsy taking VPA. Epilepsia 2003; 44 (3) 322-328
    CrossrefPubMedGoogle Scholar
  • 62 Bagheri H, Michel F, Lapeyre-Mestre M , et al. Detection and incidence of drug-induced liver injuries in hospital: a prospective analysis from laboratory signals. Br J Clin Pharmacol 2000; 50 (5) 479-484
    CrossrefPubMedGoogle Scholar
  • 63 Kenyon KW, Nappi JM. Bosentan for the treatment of pulmonary arterial hypertension. Ann Pharmacother 2003; 37 (7-8) 1055-1062
    CrossrefPubMedGoogle Scholar
  • 64 Uetrecht J. Idiosyncratic drug reactions: past, present, and future. Chem Res Toxicol 2008; 21 (1) 84-92
    CrossrefPubMedGoogle Scholar
  • 65 Lammert C, Einarsson S, Saha C, Niklasson A, Bjornsson E, Chalasani N. Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals. Hepatology 2008; 47 (6) 2003-2009
    CrossrefPubMedGoogle Scholar
  • 66 Lammert C, Bjornsson E, Niklasson A, Chalasani N. Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events. Hepatology 2010; 51 (2) 615-620
    CrossrefPubMedGoogle Scholar
  • 67 Chen M, Borlak J, Tong W. High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury. Hepatology 2013; 58 (1) 388-396
    PubMedGoogle Scholar
  • 68 Chalasani N, Aljadhey H, Kesterson J, Murray MD, Hall SD. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology 2004; 126 (5) 1287-1292
    CrossrefPubMedGoogle Scholar
  • 69 Ekstedt M, Franzén LE, Mathiesen UL, Holmqvist M, Bodemar G, Kechagias S. Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow-up study. J Hepatol 2007; 47 (1) 135-141
    CrossrefPubMedGoogle Scholar
  • 70 Lewis JH, Mortensen ME, Zweig S, Fusco MJ, Medoff JR, Belder R ; Pravastatin in Chronic Liver Disease Study Investigators. Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial. Hepatology 2007; 46 (5) 1453-1463
    CrossrefPubMedGoogle Scholar
  • 71 Bachs L, Parés A, Elena M, Piera C, Rodés J. Effects of long-term rifampicin administration in primary biliary cirrhosis. Gastroenterology 1992; 102 (6) 2077-2080
    CrossrefPubMedGoogle Scholar
  • 72 Prince MI, Burt AD, Jones DE. Hepatitis and liver dysfunction with rifampicin therapy for pruritus in primary biliary cirrhosis. Gut 2002; 50 (3) 436-439
    CrossrefPubMedGoogle Scholar
  • 73 Cascio A, Scarlata F, Giordano S, Antinori S, Colomba C, Titone L. Treatment of human brucellosis with rifampin plus minocycline. J Chemother 2003; 15 (3) 248-252
    CrossrefPubMedGoogle Scholar
  • 74 Wu JC, Lee SD, Yeh PF , et al. Isoniazid-rifampin-induced hepatitis in hepatitis B carriers. Gastroenterology 1990; 98 (2) 502-504
    PubMedGoogle Scholar
  • 75 Ungo JR, Jones D, Ashkin D , et al. Antituberculosis drug-induced hepatotoxicity. The role of hepatitis C virus and the human immunodeficiency virus. Am J Respir Crit Care Med 1998; 157 (6 Pt 1) 1871-1876
    CrossrefPubMedGoogle Scholar
  • 76 Wong WM, Wu PC, Yuen MF , et al. Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection. Hepatology 2000; 31 (1) 201-206
    CrossrefPubMedGoogle Scholar
  • 77 Patel PA, Voigt MD. Prevalence and interaction of hepatitis B and latent tuberculosis in Vietnamese immigrants to the United States. Am J Gastroenterol 2002; 97 (5) 1198-1203
    CrossrefPubMedGoogle Scholar
  • 78 Lee BH, Koh WJ, Choi MS , et al. Inactive hepatitis B surface antigen carrier state and hepatotoxicity during antituberculosis chemotherapy. Chest 2005; 127 (4) 1304-1311
    CrossrefPubMedGoogle Scholar
  • 79 Hwang SJ, Wu JC, Lee CN , et al. A prospective clinical study of isoniazid-rifampicin-pyrazinamide-induced liver injury in an area endemic for hepatitis B. J Gastroenterol Hepatol 1997; 12 (1) 87-91
    CrossrefPubMedGoogle Scholar
  • 80 den Brinker M, Wit FW, Wertheim-van Dillen PM , et al. Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS 2000; 14 (18) 2895-2902
    CrossrefPubMedGoogle Scholar
  • 81 Bonfanti P, Landonio S, Ricci E , et al; CISAI study group. Risk factors for hepatotoxicity in patients treated with highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2001; 27 (3) 316-318
    CrossrefPubMedGoogle Scholar
  • 82 Bonacini M. Liver injury during highly active antiretroviral therapy: the effect of hepatitis C coinfection. Clin Infect Dis 2004; 38 (Suppl. 02) S104-S108
    CrossrefPubMedGoogle Scholar
  • 83 Kramer JR, Giordano TP, Souchek J, El-Serag HB. Hepatitis C coinfection increases the risk of fulminant hepatic failure in patients with HIV in the HAART era. J Hepatol 2005; 42 (3) 309-314
    CrossrefPubMedGoogle Scholar
  • 84 Sulkowski MS, Thomas DL, Mehta SH, Chaisson RE, Moore RD. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology 2002; 35 (1) 182-189
    CrossrefPubMedGoogle Scholar
  • 85 Labarga P, Soriano V, Vispo ME , et al. Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patients. J Infect Dis 2007; 196 (5) 670-676
    CrossrefPubMedGoogle Scholar